Articles related to CLINICAL STUDY

PDE4 is linked to alcohol and nicotine addiction, so the researchers prioritized apremilast, a newer PDE4 inhibitor for psoriasis, as ideal for repurposing and tested it in multiple animal strains and models, as well as a human Phase IIa study. In mouse models of genetic risk for drinking to intoxication, they discovered that apremilast reduced binge-like alcohol intake and behavioral measures of alcohol motivation.

The researchers discovered that 11 of the participants had likely somatic variants at known pathogenic UBA1 positions, and all 11 had clinical symptoms consistent with VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome. Five people (45 percent) did not meet the criteria for previous rheumatologic and/or hematologic diagnoses associated with VEXAS syndrome, but all 11 had anemia, which was macrocytic in 10 people and had concomitant thrombocytopenia in 10 people. One male patient had a pathogenic variant identified prior to the onset of VEXAS-related signs or symptoms, and two female patients had disease caused by heterozygous variants. A previously unreported UBA1 variant was found in one symptomatic patient, with in vitro data supporting a catalytic defect and pathogenicity. Disease-causing UBA1 variants were found in one of 13,591 unrelated individuals, as well as in one of 4,269 men and one in 26,238 women over the age of 50.

In a study of 563 placebo-treated patients with COVID, symptoms and viral rebound were recorded in over 30% of cases.

Long-term continuous monitoring for atrial fibrillation in older patients yielded an incidental diagnosis of sinus node dysfunction or atrioventricular block with bradycardia in 21% of patients over the age of 70. But the finding was not associated with any increased risk of syncope or sudden death.

In the study, 1,400 individuals were assessed multiple times between ages of 36 and 69 for level of physical activity. They were quantified as not active, moderately active, and most active. Cognition measurements in later life showed a dose-response relationship between sustained levels of physical activity and later-life cognition status.

Maternal immunization with 2 doses of vaccine was 97% and 53% effective against infant hospitalization from delta and omicron variants, respectively. The effectiveness of the vaccine in preventing infant hospitalization declined by nearly 20% after 16 weeks. Receiving the second dose in the third trimester yielded the greatest benefit.